Patent Application
20240164397
The present invention pertains to a new method of producing high fat concentrates of milk fat globules by microfiltration, and to the use of the high fat concentrates for production of butter or butter-like spreads.
Butter is traditionally prepared by churning of cream (35-40% w/w fat) which has been skimmed from raw milk by centrifugation. The mechanical shear applied during the churning process disrupts the membranes of the milk fat globules of the cream and causes the milk fat to aggregate in larger fat grains which can be separated from the liquid phase (the buttermilk).
WO 89/10700 discloses the production of a fat product based on milk fat where the cream is concentrated by centrifugation to a fat content of 60-85% at a temperature of 50-70 degrees C. The concentrated cream is cooled to a temperature of 15-30 degrees C., and is stored until the milk fat starts to crystallize. The cooled concentrated cream is mixed with vegetable oils in an amount calculated to at least 25% of the amount of fat in the end product. After storage the mixture is stirred gently under cooling in order to achieve a phase reversal.
US 2003/0175399 A1 discloses dairy products having a total fats content lower than or equal to 400 g/kg and a fat globule distribution such that globules of lower diameter than 2.0 micron represent 10% to 60% in weight of the total fats, and the fat globules of higher diameter than to 6 micron represent 10% to 30% in weight of the total fats. The dairy products were produced by microfiltration of milk or mixtures of milk and cream.
US 2019/0191731 A1 discloses a method of modification of dry matter composition and/or dry matter content of milk, comprising the steps of:
WO 2012/110706 discloses a method for producing cheese, comprising the steps of:
Goudedranche et al (Le Lait, INRA Editions, 2000, 80 (1), pp. 93-98) discloses separation of milk fat in small globules (SG) (diameter lower than 2 μm) and in large globules (LG) (diameter higher than 2 μm) using special ceramic microfiltration membranes. Transformations in drinking milks, yoghourts, sour cream, camembert, Swiss cheese and butters were realized from milks of which the fat content was adjusted either by reference cream or by creams issued from the SG or the LG fractions. Significant differences in texture and organoleptic properties were found in the manufactured products. Except for butter, use of milks containing small fat globules led to more onctuous products and finer textural characteristics versus products made with reference creams or with mainly large fat globules. Fat globule membrane appeared to have a high ability to bind water in cheese and so, to allow a significant increase in cheese yield.
The present inventors have discovered that new high fat concentrates of milk fat globules can be prepared by concentrating a milk fat globule-containing dairy liquid (mfl) by gentle microfiltration. The resulting milk fat globule concentrate has a taste and textural properties that are surprisingly close to that of butter despite the fact that neither mfl nor the milk fat globule concentrate have been subjected to churning. The invention therefore enables a more efficient approach for the production of butter-like products.
Thus, an aspect of the invention pertains to a method of producing a milk fat globule concentrate, the method comprising the following steps:
In addition to requiring less energy than the traditional butter-making processes, the inventors have observed that the method provides a milk fat globule concentrate that has a surprisingly high content of milk fat globule-derived phospholipids which indicates that the milk fat globule concentrate still contains a considerably amount of native milk fat globules. This has also been confirmed in Example 1 (see e.g.
Thus, another aspect of the invention pertains to a milk fat globule concentrate, preferably obtainable according to the method described herein, comprising total fat in an amount in the range of 50-85% w/w, and preferably in the range of 60-85% w/w, and having a pH in the range of 5.0-8.
The milk fat globule concentrate preferably comprises:
A more narrow aspect of the invention pertains to a milk fat globule concentrate, preferably obtainable by a method of the invention, which comprises:
A further aspect of the invention pertains to a process of preparing a butter-like milk fat-containing product (bmp), the process comprising the steps of:
Yet an aspect of the invention pertains to a bmp, preferably obtainable by a process according to the invention, the product comprising:
Yet an aspect of the invention pertains to the use of the milk fat globule concentrate of the invention for producing a bmp, and preferably for producing butter.
An aspect of the invention pertains to a method of producing a milk fat globule concentrate, the method comprising the following steps:
The milk fat globule concentrate obtained by the method is the concentrated milk fat globule-containing product resulting from the method steps.
In the context of the present invention the term “milk fat globule-containing dairy liquid” or “mfl” pertains to a dairy liquid derived from ruminant milk, and which contains milk fat globules from the original milk source. The milk fat globules of the mfl preferably resemble the milk fat globules of the original milk source and have preferably been concentrated with no or only limited membrane damage during processing. It is particularly preferred that most, if not substantially all, of the fat of the mfl is present in the form of milk fat globules.
The original milk source is preferably milk obtained from one or more ruminant species, and is preferably milk from one or more of cow, sheep, goat, buffalo, camel, llama, mare and/or deer. It is particularly preferred that the mfl is derived from cow milk.
Preferably, the fat of the mfl is milk fat and the proteins of the mfl are proteins found in milk.
In some preferred embodiments of the invention the mfl of step 1) comprises or even consists of raw milk, whole milk, milk-derived cream, or a mixture thereof.
Preferably the mfl is a cream having a total fat content in the range of 10-50% w/w, preferably prepared by concentrating milk fat globules from milk, preferably by centrifugation or alternatively by microfiltration.
In the context of the present invention the term “fat” pertains to the sum of triglycerides, diglycerides, and monoglycerides and is quantified according to Analysis B.
The mfl of step 1) preferably has a pH in the range of 5.0-8, more preferably 5.5-8.0, even more preferably 6.0-7.5, and most preferably 6.4-7.0.
While a wide range of temperatures can be used, the inventors have found it advantageous that the mfl of step 1) has a temperature in the range of 40-70 degrees C., more preferably 45-70 degrees C., even more preferably 50-65 degrees C., and most preferably 55-60 degrees C.
The mfl of step 1) preferably comprises total protein in an amount in the range of 0.5-5% w/w, more preferably 1-4% w/w, even more preferably 1.5-3.5% w/w, and most preferably 1.5-3.0% w/W.
Alternatively, but also preferred, the mfl of step 1) may comprise total protein in an amount in the range of 0.5-5% w/w, more preferably 0.5-4% w/w, even more preferably 0.5-3% w/w, and most preferably 0.5-1% w/w.
In preferred embodiments of the invention the mfl of step 1) comprises total fat in an amount in the range of 5-50% w/w, more preferably 10-48% w/w, even more preferably 30-46% w/w, and most preferably 35-44% w/w.
The mfl of step 1) typically comprises carbohydrate in an amount in the range of 0-10% w/w, more preferably 0.1-8% w/w, even more preferably 0.5-6% w/w, and most preferably 1-5% w/w.
The mfl of step 1) typically has a weight ratio between total fat and total protein in the range of 5-50, more preferably 10-40, even more preferably 15-30, and most preferably 17-25.
It is particularly preferred that the preparation of the mfl has not involved size reduction of milk fat globules, e.g. by homogenisation and the inventors have seen indications that non-homogenised mfls perform better in the present invention than homogenised mfls, and provide concentrates containing milk fat globules with less damaged globule membranes. It is therefore preferred that the mfl is a non-homogenised mfl. Milk fat globule concentrates based on non-homogenized mfl are also preferred for the preparation of the present bmp.
While not always necessary, it is often preferred that the mfl is heat-treated prior to step 2). Preferably, the mfl has been heat-treated at most 60 minutes prior to the microfiltration, more preferably at most 30 minutes prior to the microfiltration, even more preferred at most 10 minutes prior to the microfiltration and most preferably at most 5 minutes prior to the microfiltration.
The heat-treatment prior to the microfiltration preferably involves heating the mfl to a temperature of at least 70 degrees C. for a duration sufficient to obtain at least partial microbial reduction. The duration depends on the temperature and the desired level of microbial reduction. Preferably, the duration is sufficient to reduce content of colony forming units by at least 99%, more preferably by at least 99.9%, even more preferably by at least 99.99% and most preferably by at least 99.999%.
Useful heat-treatments are e.g. 70-80 degrees C. for 5-300 seconds.
Preferably, the heat-treatment prior to the microfiltration, if used, denatures at most 50% of the beta-lactoglobulin, more preferably at most 30% of the beta-lactoglobulin, even more preferably at most 25% of the beta-lactoglobulin, and most preferably at most 20% of the beta-lactoglobulin.
The heat-treatment prior to the microfiltration, if used, preferably denatures 1-50% of the beta-lactoglobulin, more preferably 2-30% of the beta-lactoglobulin, even more preferably 3-25% of the beta-lactoglobulin, and most preferably 4-20% of the beta-lactoglobulin.
After the heat-treatment the mfl is preferably cooled to the temperature desired for microfiltration.
Step 2) involves subjecting the mfl to microfiltration to concentrate the mfl to a total fat content of at least 50% w/w, wherein the microfiltration preferably involves the use of a ceramic microfiltration membrane. The microfiltration is operated with one or more membranes that keep the fat globules in the retentate stream(s) and allows smaller components such as free whey proteins, lactose and minerals to enter the permeate stream(s).
The microfiltration of step 2) increases the content of fat on a weight percent basis relative to the fat content of the mfl. Therefore if the mfl already has a fat content of 50% w/w, the microfiltration of step 2) concentrates the mfl to a total fat content higher than 50% w/w.
The MF membrane may also be permeable to at least some of the casein micelles, typically the smaller of casein micelles. Alternatively and sometimes preferred, the MF membrane may be permeable to a substantial amount of the casein micelles.
Step 2) may be implemented as a batch process step, a semi-batch process step or a continuous process step. Implementation as a continuous process step is particularly preferred.
In some preferred embodiments of the invention, the microfiltration of step 2) furthermore involves diafiltration, preferably using a diluent in the form of water or an aqueous solution. Useful diluents are e.g. water, reverse osmosis permeate of milk or whey, nanofiltration permeate of milk or whey, and/or ultrafiltration permeate of milk or whey. The diluent is preferably essentially free of protein.
The inventors have found that further protein reduction is possible. In some preferred embodiments of the invention, the diluent for diafiltration comprises a chelating agent capable of binding calcium. The chelating agent is preferably selected from the group consisting of citrate, EDTA, orthophosphate, and/or hydrogen phosphate. The chelating agent is preferably present in an amount sufficient to release at least some of the casein from the casein micelles.
Alternatively or additionally it is sometimes preferred that the mfl has been added a chelating agent capable of binding calcium. The chelating agent is preferably selected from the group consisting of citrate, EDTA, orthophosphate, and/or hydrogen phosphate. The chelating agent is preferably present in the mfl in an amount sufficient to release at least some of the casein from the casein micelles.
In other preferred embodiments of the invention, the microfiltration of step 2) does not involve diafiltration.
In some preferred embodiments of the invention, in step 2) the mfl is subjected to MF to concentrate the mfl to a total fat content of at least 52% w/w, more preferably at least 54% w/w, even more preferably at least 58% w/W.
The mfl is preferably concentrated to a total fat content of in the range of 60-85% w/w, more preferably 62-85% w/w, more preferably 65-85% w/w, even more preferably 70-85% w/w, and most preferably 72-82% w/w.
Alternatively, but also preferred, the mfl may e.g. be concentrated to a total fat content of in the range of 50-85% w/w, more preferably 52-85% w/w, even more preferably 54-85% w/w, and most preferably 56-82% w/W.
Concentration of the mfl to a total fat content of 50-70% w/w, more preferably 52-68% w/w, even more preferably 54-66% w/w, and most preferably 56-64% w/w is often advantageous if the milk fat globule concentrate subsequently is to be processed into a low fat, butter-like product.
In some preferred embodiments of the invention the mfl is concentrated to a total fat content of in the range of 70-85% w/w, more preferably 73-85% w/w, even more preferably 76-85% w/w, and most preferably 80-85% w/w.
Concentration of the mfl to a total fat content of 81-85% w/w, more preferably 81-85% w/w, even more preferably 82-85% w/w, and most preferably 82-84% w/w is advantageous if the milk fat globule concentrate subsequently is to be processed into a butter-like product, and particularly into butter as such.
The microfiltration membrane is preferably capable of retaining a substantial portion of the milk fat globules but permeable to native beta-lactoglobulin and preferably also other whey proteins. Often it is also preferred that the microfiltration membrane is permeable to at least the smallest casein micelles.
The inventors have found that it is advantageous to avoid membranes with too large pore sizes as these are blocked by milk fat globules during operation.
In some preferred embodiments of the invention the microfiltration membrane has a pore size in the range of 0.05-2 micron, more preferably 0.05-1.5, even more preferably 0.1-0.8, and most preferably 0.2-0.4 micron.
In other preferred embodiments of the invention the microfiltration membrane has a pore size in the range of 0.1-2 micron, more preferably 0.1-1.5, even more preferably 0.2-1.0, and most preferably 0.2-0.8 micron.
The inventors have found that for some applications it is beneficial to increase the weight ratio between casein and whey protein and have seen indications that it provides a milk fat globule concentrate with improved stability.
Preferred embodiments of the invention the step 2) is arranged and operated to provide a milk fat globule concentrate having a weight ratio between casein and whey protein of 80:20-99:1, more preferably 80:20-98:2, even more preferably 85:15-98:2, and most preferably 90:10-98:2.
The microfiltration of step 2) preferably involves the use of a ceramic MF membrane. Preferably, the MF membranes used in step 2) are ceramic MF membranes.
The inventors have observed that polymeric microfiltration membranes are unsuitable for concentrating milk or cream to very high fat contents such as e.g. 50% w/w or higher.
In some preferred embodiments of the invention the microfiltration of step 2) involves the use of a ceramic membrane comprising or even consisting of metal oxide and/or metal carbide.
In other preferred embodiments of the invention the microfiltration of step 2) involves the use of a ceramic membrane comprising or even consisting of aluminium oxides, titanium oxides, zirconium oxides, or a combination thereof.
In further preferred embodiments of the invention the microfiltration of step 2) involves the use of a ceramic membrane comprising or even consisting of aluminium carbide, silicon carbide, or a combination thereof.
The inventors have found it advantageous that the MF membrane is a ceramic membrane comprising or even consisting of silicon carbide. Preferably, the MF membrane(s) used in step 2) are ceramic membrane(s) comprising or even consisting of silicon carbide.
The inventors have furthermore found it advantageous to use hydrophilic MF membranes and have seen indications that the use of hydrophilic MF membrane for preparing milk fat globule concentrates containing at least 60% fat, or even at least 50% w/w fat, provides less damage to the milk fat globules.
In some preferred embodiments of the invention the MF membrane has a contact angle against a droplet of distilled water at 20 degrees C. of at most 40 degrees, more preferably at most 30 degrees, even more preferably at most 20 degrees, and most preferably at most 15 degrees.
The microfiltration may for example employ monotube or multichannel configurations. Multichannel configuration is particularly preferred.
The microfiltration may be performed in a number of ways e.g. in batch, feed-batch or continuous mode and may involve only a single filter module or multitude of filter modules arranged in series and/or in parallel.
The inventors have found it advantageous to use the mfl at a temperature of at least 40 degrees C. in step 2) in order to avoid or at least reduce shear damage of the milk fat globules. Without being bound by theory, it is believed that the low content of solid fat in the milk fat globules at 40 degrees C. makes the fat globules more flexible and less likely to disrupt during the microfiltration.
The inventors have furthermore found it advantageous to limit or even avoid the exposure to protein denaturing temperatures during the microfiltration.
Preferably, the temperature of the mfl and MF retentate(s) derived from the mfl during the step 2) is in the range of 40-65 degrees C.; more preferably 45-65 degrees C., even more preferably 50-65 degrees C., and most preferably 50-60 degrees C.
In the context of the present invention the term “MF retentate(s)” pertain to both the final retentate resulting from the microfiltration operation of step 2) and to intermediate milk fat globule-containing MF retentates which are present in some implementations of step 2), e.g. if diafiltration is used and/or if the microfiltration involves several MF units operates in series.
The inventors have seen indications that operating the microfiltration with a relatively low transmembrane pressure provides less shear and hence less damage on the milk fat globule membranes than microfiltration at very high transmembrane pressures.
In some preferred embodiments of the invention the microfiltration involves a transmembrane pressure in the range of 0.1-10 bar, more preferably 0.1-5 bar, more preferably 0.2-3 bar, even more preferably 0.3-1.0 bar, and most preferably 0.4-0.6 bar.
In other preferred embodiments of the invention the microfiltration involves a transmembrane pressure of at most 10 bar, more preferably at most 5 bar, more preferably at most 3 bar, even more preferably at most 1 bar, and most preferably at most 0.6 bar.
In further preferred embodiments of the invention the microfiltration involves a transmembrane pressure of at most 0.4 bar, more preferably at most 0.3 bar, even more preferably at most 0.2 bar, and most preferably at most 0.1 bar.
The microfiltration of step 2) is preferably arranged and operated to lose at most 2% w/w of the total fat of the mfl to the microfiltration permeate, more preferably at most 1.5% w/W, even more preferably at most 1.0% w/w, and most preferably at most 0.8% w/w.
In the context of the present invention the term “arranged and operated” means that the microfiltration is implemented and operated to fulfil the mentioned requirement. This means e.g. making an appropriate membrane selection and appropriate choices of operational parameters. Microfiltration as such is well-known to the skilled person and the skilled person is capable of making the appropriate selections and choices based on the guidance provided herein and his/her general technical knowledge.
In other preferred embodiments of the invention the microfiltration of step 2) is arranged and operated to lose at most 0.5% w/w of the total fat of the mfl to the microfiltration permeate, more preferably at most 0.3% w/w, even more preferably at most 0.1% w/w, and most preferably at most 0.05% w/w.
In further preferred embodiments of the invention the microfiltration of step 2) is arranged and operated to lose at most 45% w/w of the total phospholipid of the mfl to the microfiltration permeate, more preferably at most 30% w/w, even more preferably at most 20% w/w, and most preferably at most 16% w/w.
In some preferred embodiments of the invention the microfiltration of step 2) is arranged and operated to lose at most 10% w/w of the total phospholipid of the mfl to the microfiltration permeate, more preferably at most 6% w/w, even more preferably at most 4% w/w, and most preferably at most 2% w/W.
In the context of the present invention the term “microfiltration permeate” pertains to the permeate stream or combined permeate streams resulting from the microfiltration of step 2).
The inventors have observed that it often is beneficial to control the permeate flux during the microfiltration by applying a back-pressure at the permeate side of the MF membrane, e.g. using an appropriate valve. The back-pressure is preferably 0-5 bar and more preferably 0-3 bar.
It is often preferred that the back-pressure at the permeate side of the MF membrane is lower than transmembrane pressure.
It may furthermore be preferred to subject the milk fat globule concentrate to a heat-treatment. The heat-treatment of the milk fat globule concentrate preferably involves heating the milk fat globule concentrate to a temperature of at least 70 degrees C. for a duration sufficient to obtain at least partial microbial reduction. The duration depends on the temperature and the desired level of microbial reduction. Preferably, the duration is sufficient to reduce content of colony forming units by at least 99%, more preferably by at least 99.9%, even more preferably by at least 99.99% and most preferably by at least 99.999%.
Useful heat-treatments are e.g. 70-80 degrees C. for 5-300 seconds.
Preferably, the heat-treatment of the milk fat globule concentrate, if used, denatures at most 50% of the beta-lactoglobulin, more preferably at most 30% of the beta-lactoglobulin, even more preferably at most 25% of the beta-lactoglobulin, and most preferably at most 20% of the beta-lactoglobulin.
The heat-treatment of the milk fat globule concentrate, if used, preferably denatures 1-50% of the beta-lactoglobulin, more preferably 2-30% of the beta-lactoglobulin, even more preferably 3-25% of the beta-lactoglobulin, and most preferably 4-20% of the beta-lactoglobulin.
After the heat-treatment the milk fat globule concentrate is preferably cooled or alternative subjected to further processing.
It is preferred that step 2) does not involve concentration of milk fat globules by centrifugation.
The method of the invention may be implemented as a batch process, a semi-batch process or a continuous process. Implementation as a continuous process is particularly preferred.
Another aspect of the invention pertains to a milk fat globule concentrate, preferably obtainable according to the method described herein, comprising total fat in an amount in the range of 50-85% w/w, and preferably in the range of 60-85% w/w, and having a pH in the range of 5.0-8.
The milk fat globule concentrate preferably comprises:
In some preferred embodiments of the invention the milk fat globule concentrate comprises:
In other preferred embodiments of the invention the milk fat globule concentrate comprises:
The milk fat globule concentrate preferably comprises total fat in an amount in the range of 62-85% w/w, more preferably 65-85% w/w, more preferably 70-85% w/w, even more preferably 70-82% w/w, and most preferably 75-82% w/w.
Alternatively, but also preferred, the milk fat globule concentrate may comprise total fat in an amount in the range of 50-85% w/w, more preferably 52-85% w/w, even more preferably 54-85% w/w, and most preferably 56-82% w/w. It is equally preferred that milk fat globule concentrate may comprise water in an amount in the range of 10-49% w/w, more preferably 10-47% w/w, even more preferably 10-45% w/w, and most preferably 10-43% w/w.
A milk fat globule concentrate having a total fat content of 50-70% w/w, more preferably 52-68% w/w, even more preferably 54-66% w/w, and most preferably 56-64% w/w is often advantageous if the milk fat globule concentrate subsequently is to be processed into a low fat, butter-like product. It is equally preferred that milk fat globule concentrate may comprise water in an amount in the range of 25-49% w/w, more preferably 25-47% w/w, even more preferably 25-45% w/w, and most preferably 25-43% w/w.
The milk fat globule concentrate preferably comprises total protein in an amount in the range of 0.1-5% w/w, more preferably 0.2-3% w/w, even more preferably 0.3-1.5% w/w, and most preferably 0.4-1.0% w/W.
Alternatively but also preferred the milk fat globule concentrate may comprise total protein in an amount in the range of 0.4-5% w/w, more preferably 0.5-3% w/w, even more preferably 0.6-1.5% w/w, and most preferably 0.7-1.2% w/w.
The inventors have found it advantageous to limit the content of protein present in the milk fat globule concentrate and particularly to limit the content of protein that is not bound to the milk fat globules.
In some preferred embodiments of the invention the milk fat globule concentrate comprises protein which is not bound to fat globules in an amount in the range of 0-2% w/w, more preferably 0-1% w/w, even more preferably 0-0.5% w/w, and most preferably 0-0.3% w/w.
In some preferred embodiments of the invention the milk fat globule concentrate has a weight ratio between casein and whey protein of 70:30-99:1, more preferably 80:20-98:2, even more preferably 85:15-98:2, and most preferably 90: 10-98:2.
In some preferred embodiments of the invention the milk fat globule concentrate comprises carbohydrate in an amount in the range of 0-4% w/w, more preferably 0-2% w/w, even more preferably 0-1% w/w, and most preferably 0-0.5% w/w.
In some preferred embodiments of the invention the milk fat globule concentrate comprises lactose in an amount in the range of 0-4% w/w, more preferably 0-2% w/w, even more preferably 0-1% w/w, and most preferably 0-0.5% w/w.
In some preferred embodiments of the invention the milk fat globule concentrate has an ash content in the range of 0-4% w/w, more preferably 0.05-2% w/w, even more preferably 0.1-1.0% w/w, and most preferably in the range of 0.2-0.4%.
In some preferred embodiments of the invention the milk fat globule concentrate has a pH in the range of 5-8, more preferably 5.5-8.0, even more preferably 6.0-7.5, and most preferably 6.4-7.0.
In other preferred embodiments of the invention the milk fat globule concentrate has a pH in the range of 6.0-7.5, more preferably 6.0-7.0, even more preferably 6.4-7.0% w/w, and most preferably in the range of 6.4-6.8.
In some preferred embodiments of the invention the milk fat globule concentrate has a weight ratio between total phospholipid and total fat of at least 0.0022, more preferably at least 0.0024, even more preferably at least 0.0028, and most preferably at least 0.0030.
In other preferred embodiments of the invention the milk fat globule concentrate has a weight ratio between total phospholipid and total fat in the range of 0.0022-0.02, more preferably 0.0024-0.01, even more preferably 0.0028-0.007, and most preferably 0.0030-0.005.
In further preferred embodiments of the invention the milk fat globule concentrate has a weight ratio between total phospholipid and total fat of at least 0.0033, more preferably at least 0.0035, even more preferably at least 0.0037, and most preferably at least 0.0038.
In even further preferred embodiments of the invention the milk fat globule concentrate has a weight ratio between total phospholipid and total fat of 0.0033-0.02, more preferably 0.0035-0.01, even more preferably 0.0037-0.007, and most preferably 0.0038-0.005.
In some preferred embodiments of the invention the milk fat globule concentrate comprises at least 55% w/w of the total phospholipid of the mfl, more preferably at least 70% w/w, even more preferably at least 80% w/w, and most preferably at least 84% w/w.
In other preferred embodiments of the invention the milk fat globule concentrate comprises at least 90% w/w of the total phospholipid of the mfl, more preferably at least 94% w/w, even more preferably at least 96% w/w, and most preferably at least 98% w/w.
In some preferred embodiments of the invention the milk fat globule concentrate contains at most 10000 colony forming units per g, more preferably at most 2000 colony forming units per g, even more preferably at most 1000 colony forming units per g, and most preferably at most 500 colony forming units per g.
The milk fat globule concentrate of the invention is preferably obtainable by the method of the invention.
The milk fat globule concentrate of the present invention has a quality that allows it to be used directly as a butter-like milk fat-containing spread (see e.g.
Process-wise, the present method offers a simple yet robust alternative to traditional butter production as the present method does not require cream-aging prior to a churning step and avoids the energy-intensive churning step that the traditional butter process requires to provoke phase inversion of the milk fat globules. The present method therefore requires less energy than traditional butter churning and can be implemented without time-consuming aging steps of the conventional method.
Furthermore, the MF permeate that is the by-product of the present method is more useful than traditional buttermilk and is more easily incorporated into other dairy products. It furthermore has a lower fat content than traditional buttermilk. Therefore, the present method minimizes the loss of fat into the buttermilk and increases the yield of butter like products.
Yet an aspect of the invention pertains to a process of preparing a butter-like milk fat-containing product (bmp), the process comprising the steps of:
An advantage of this process is that that it reduces, or even avoids, the production of buttermilk side streams as most, or even all, of the water of the milk fat globule concentrate stays in the butter-like milk fat-containing product.
The sub-steps are process steps that can be performed during the process, e.g. a single time or even several times if desired.
The sub-step(s) modify the milk fat globule concentrate and/or the subsequent product stream(s) that comprises the milk fat globule concentrate. The term “subsequent product stream” pertains to further milk fat compositions comprising the milk fat globule concentrate, which compositions are obtained during the process. The bmp is the product stream obtained by the final stage of the process.
The sub-steps of step ii) can be performed in any order, with the exception that if step ii-e) is used, any sub-steps ii-a), ii-c), and ii-d) are preferably performed prior to step ii-e). The inventors have found that addition of further ingredients according to sub-steps ii-a) and ii-d), and mechanical shearing according to sub-step ii-c) are challenging to perform after the bmp has been packaged and therefore it is preferred to any of these steps prior to a packaging step. Processing by low temperature-holding according of sub-step ii-b) can be performed both prior to and/or after a packaging step.
The sub-step(s) modify the milk fat globule concentrate and/or the subsequent product stream(s) that comprises the milk fat globule concentrate. The term “subsequent product stream” pertains to further milk fat compositions comprising the milk fat globule concentrate, which compositions are obtained during the process. The bmp is the product stream obtained by the final stage of the process.
Sub-step ii-a) involves addition of one or more of sodium chloride, colour, butter flavour, water, a fermented dairy product, and/or a combination thereof.
In some preferred embodiments of the invention step ii-a) furthermore involves blending the added ingredients with the milk fat globule concentrate and/or a subsequent product stream comprising the milk fat globule concentrate.
In some embodiments, it is preferred that the blending causes at least some phase inversion.
In other embodiments, it is preferred that the blending causes nor or only limited phase inversion.
The blending of step ii-a) preferably takes place at a temperature of 5-20 degrees C., more preferably 10-17 degrees C., and most preferably 12-15 degrees C.
Sub-step ii-b) is a cold holding step and involves holding the composition in question at temperature(s) of at most 20 degrees C. for a duration sufficient for forming fat crystals in a least some of the milk fat globules.
In some preferred embodiments of the invention step ii-b) involves holding at a temperature of at most 18 degrees C., more preferably at most 17 degrees C., and most preferably at most 15 degrees C.
In some preferred embodiments of the invention step ii-b) involves holding at a temperature of 5-20 degrees C., more preferably 10-17 degrees C., and most preferably 12-15 degrees C.
Sub-step ii-b) may furthermore comprise one or more aging steps similar to those used for cream-aging prior to butter churning.
It is often preferred that any processing that proceeds sub-step ii-b) is performed at a temperature 5-20 degrees C., more preferably 5-17 degrees C., and most preferably 5-15 degrees C.
Sub-step ii-c) involves mechanical shearing, preferably to obtain at least some phase inversion, meaning that at least some of milk fat globules merge to form larger milk fat regions.
The mechanical shearing may be performed by dedicated butter-making equipment, a mixer, a scraped surface heat exchanger, or a combination thereof. Preferably, the mechanical shearing is performed by a mixer and/or a scraped surface heat exchanger. In some preferred embodiments the mechanical shearing of step ii-c) involves churning, e.g. using a device for butter churning.
The temperature of the composition subjected to sub-step ii-c is typically at most 20 degrees C. and preferably less than 20 degrees C. In some preferred embodiments of the invention the temperature of the composition subjected to sup-step ii-c is 5-20 degrees C., more preferably 10-17 degrees C., and most preferably 12-15 degrees C.
In some preferred embodiments of the invention step ii) involves:
Sub-step ii-d) involves addition of a further fat source, preferably a vegetable oil.
In some preferred embodiments of the invention the vegetable oil comprises or even consists of selected from the group of consisting of sunflower oil, corn oil, sesame oil, soya bean oil, palm oil, linseed oil, grape seed oil, rapeseed oil, olive oil, groundnut oil, and combinations thereof. Rapeseed oil is the presently preferred vegetable oil.
In some preferred embodiments of the invention sub-step ii-d) furthermore involves blending the added fat source with the milk fat globule concentrate and/or a subsequent product stream, preferably without provoking phase inversion.
The blending of step ii-d) preferably takes place at a temperature of 5-20 degrees C., more preferably 10-17 degrees C., and most preferably 12-15 degrees C.
Sub-step ii-e) involves packaging the bmp in a suitable container.
The bmp is preferably filled in suitable containers, e.g. in the form of plastic tubs. Each container typically contains 5-2000 gram bmp. The containers are preferably sealed with cover leaves, optionally welded, and closed with plastic lids. Finally, the containers may be further packed in boxes which are palletized.
The bmp preferably has a temperature of 8-16 degrees C., most preferably 10-14 degrees C. during packaging and if its temperature is higher prior to sub-step ii-e) the bmp can be cooled, preferably using a scraped surface heat-exchanger, to the desired temperature.
In some preferred embodiments of the invention step ii) involves:
In some preferred embodiments of the invention step ii-d) is performed after step b) and preferably prior, during and/or after step ii-c).
Sub-steps ii-a) and/or ii-d) may preferably be performed simultaneously with a step ii-c) in embodiments where phase inversion is desired.
In some preferred embodiments of the invention similar to Example 2, step ii) comprises the sub-steps:
In some preferred embodiments of the invention similar to Example 3, step ii) comprises the sub-steps:
The inventors have found that it is often preferred to add 40-60% of the total amount of vegetable oil after sub-step ii-c) and the remaining part prior to or during sub-step ii-c).
In other preferred embodiments of the invention similar to Example 3, step ii) comprises the sub-steps:
Typically, the milk fat globule concentrate is used in an amount sufficient to provide at least 20% w/w of the total fat of the bmp, more preferably at least 25% w/w, even more preferably at least 30% w/w, and most preferably at least 40% w/w of the total fat of the bmp.
In some preferred embodiments of the invention the milk fat globule concentrate is used in an amount sufficient to provide at 20-60% w/w of the total fat of the bmp, more preferably at least 21-50% w/w, even more preferably 22-45% w/w, and most preferably at least 23-40% w/w of the total fat of the bmp.
In other preferred embodiments of the invention the milk fat globule concentrate is used in an amount sufficient to provide at least 50% w/w of the total fat of the bmp, more preferably at least 60% w/w, even more preferably at least 80% w/w, and most preferably at least 90% w/w of the total fat of the bmp.
In further preferred embodiments of the invention, for example to prepare a bmp having a chemical composition similar to butter, the milk fat globule concentrate is used in an amount sufficient to provide at least 95% w/w of the total fat of the bmp, more preferably at least 97% w/w, even more preferably at least 99% w/w, and most preferably approx. 100% w/w of the total fat of the bmp.
In even further preferred embodiments of the invention, the milk fat globule concentrate is used in an amount sufficient to provide at 50-95% w/w of the total fat of the bmp, more preferably 55-90% w/w, even more preferably 55-85% w/w, and most preferably 60-80% w/w of the total fat of the bmp.
The bmp typically comprises total protein in an amount in the range of 0.1-5% w/w, more preferably 0.2-4% w/w, even more preferably 0.4-2% w/w, and most preferably 0.5-1.0% w/w.
In some preferred embodiments of the invention the bmp has a weight ratio between casein and whey protein of 70:30-99:1, more preferably 80:20-98:2, even more preferably 85:15-98:2, and most preferably 90:10-98:2.
In some preferred embodiments of the invention the bmp comprises total fat in an amount in the range of 50-90% w/w, more preferably 55-85% w/w, even more preferably 60-84% w/w, and most preferably 80-84% w/w.
In other preferred embodiments of the invention the bmp comprises total fat in an amount in the range of 35-60% w/w, more preferably 35-50% w/w, even more preferably 36-45% w/w, and most preferably 38-42% w/W.
In further preferred embodiments of the invention the bmp comprises total fat in an amount in the range of 40-80% w/w, more preferably 45-75% w/w, even more preferably 50-70% w/w, and most preferably 55-65% w/w.
The bmp typically comprises carbohydrate in an amount in the range of 0-10% w/w, more preferably 0-8% w/w, even more preferably 0-6% w/w, and most preferably 0-5% w/w.
In some preferred embodiments of the invention the bmp comprises carbohydrate in an amount in the range of 0.1-10% w/w, more preferably 0.2-8% w/w, even more preferably 0.3-6% w/w, and most preferably 0.4-5% w/w.
The inventors have found that the milk fat globule concentrate has a consistency and spreadability which is surprisingly close to that of butter, even though the milk fat globules have not been subjected to churning. Thus, in some preferred embodiments of the invention the bmp is an oil-in-water emulsion, or at least partially an oil-in-water emulsion.
In other preferred embodiments of the invention the bmp is a water-in-oil emulsion, preferably wherein the milk fat globule concentrate has been processed to provide a bmp having a microstructure similar to butter.
Often, the bmp comprises both segments of oil-in-water emulsion and segments of water-in-oil emulsion, for example when the mechanical shearing of step ii-c) has caused some phase inversion but not complete phase inversion.
In some preferred embodiments of the invention similar to Example 2,
In some preferred embodiments of the invention similar to Example 3:
As mentioned above, the inventors have found that it is often preferred to add 40-60% of the total amount of vegetable oil prior to or during sub-step ii-c) and the remaining part after sub-step ii-c).
Sub-steps ii-a) and/or ii-d) may preferably be performed simultaneously with a step ii-c) in embodiments where phase inversion is desired.
In other preferred embodiments of the invention similar to Example 3:
Yet an aspect of the invention pertains to a bmp, preferably obtainable by a process of the invention, the product comprising:
Yet an aspect of the invention pertains to the use of the milk fat globule concentrate of the invention for producing a bmp, and preferably for producing butter.
Preferred numbered embodiments of the invention are described in the following:
Numbered embodiment 1. A method of producing a milk fat globule concentrate, the method comprising the following steps:
Numbered embodiment 2. The method according to numbered embodiment 1, wherein the mfl of step 1) comprises or even consists of raw milk, whole milk, milk-derived cream, or a mixture thereof.
Numbered embodiment 3. The method according to numbered embodiment 1 or 2, wherein the mfl is a cream having a total fat content in the range of 10-50% w/w, preferably prepared by concentrating milk fat globules from milk, preferably by centrifugation.
Numbered embodiment 4. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) has a pH in the range of 5.0-8, more preferably 5.5-8.0, even more preferably 6.0-7.5, and most preferably 6.4-7.0.
Numbered embodiment 5. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) has a temperature in the range of 40-70 degrees C., more preferably 45-70 degrees C., even more preferably 50-65 degrees C., and most preferably 55-60 degrees C.
Numbered embodiment 6. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) comprises total protein in an amount in the range of 0.5-5% w/w, more preferably 1-4% w/w, even more preferably 1.5-3.5% w/w, and most preferably 1.5-3.0% w/w.
Numbered embodiment 7. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) comprises total protein in an amount in the range of 0.5-5% w/w, more preferably 0.5-4% w/w, even more preferably 0.5-3% w/w, and most preferably 0.5-1% w/w.
Numbered embodiment 8. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) comprises total fat in an amount in the range of 5-50% w/w, more preferably 10-48% w/w, even more preferably 30-46% w/w, and most preferably 35-44% w/W.
Numbered embodiment 9. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) comprises carbohydrate in an amount in the range of 0-10% w/w, more preferably 0.1-8% w/w, even more preferably 0.5-6% w/w, and most preferably 1-5% w/w.
Numbered embodiment 10. The method according to any of the preceding numbered embodiments, wherein the mfl of step 1) has a weight ratio between total fat and total protein in the range of 5-50, more preferably 10-40, even more preferably 15-30, and most preferably 17-25.
Numbered embodiment 11. The method according to any of the preceding numbered embodiments, wherein the microfiltration of step 2) furthermore involves diafiltration, preferably using water or an aqueous solution as diluent.
Numbered embodiment 12. The method according to any to numbered embodiment 11 wherein the diluent for diafiltration comprises a chelating agent, preferably selected from the group consisting citrate, EDTA, orthophosphate, and/or hydrogen phosphate.
Numbered embodiment 13. The method according to any of the preceding numbered embodiments, wherein the microfiltration of step 2) does not involve diafiltration.
Numbered embodiment 14. The method according to any of the preceding numbered embodiments, wherein the mfl is concentrated to a total fat content of in the range of 60-85% w/w, more preferably 62-85% w/w, more preferably 65-85% w/w, even more preferably 70-85% w/w, and most preferably 72-82% w/w.
Numbered embodiment 15. The method according to any of the preceding numbered embodiments, wherein the mfl is concentrated to a total fat content of in the range of 70-85% w/w, more preferably 73-85% w/w, even more preferably 76-85% w/w, and most preferably 80-85% w/W.
Numbered embodiment 16. The method according to any of the preceding numbered embodiments wherein the microfiltration membrane has a pore size in the range of 0.05-2 micron, more preferably 0.05-1.5, even more preferably 0.1-0.8, and most preferably 0.2-0.4 micron.
Numbered embodiment 17. The method according to any of the preceding numbered embodiments wherein the microfiltration membrane has a pore size in the range of 0.1-2 micron, more preferably 0.1-1.5, even more preferably 0.2-1.0, and most preferably 0.2-0.8 micron.
Numbered embodiment 18. The method according to any of the preceding numbered embodiments wherein the MF membrane is a ceramic membrane.
Numbered embodiment 19. The method according to any of the preceding numbered embodiments wherein the MF membrane is a ceramic membrane comprising or even consisting of metal oxide and/or metal carbide.
Numbered embodiment 20. The method according to any of the preceding numbered embodiments wherein the MF membrane is a ceramic membrane comprising or even consisting of aluminium oxides, titanium oxides, zirconium oxides, or a combination thereof.
Numbered embodiment 21. The method according to any of the preceding numbered embodiments wherein the MF membrane is a ceramic membrane comprising or even consisting of aluminium carbide, silicon carbide, or a combination thereof.
Numbered embodiment 22. The method according to any of the preceding numbered embodiments wherein the MF membrane is a ceramic membrane comprising or even consisting of silicon carbide.
Numbered embodiment 23. The method according to any of the preceding numbered embodiments wherein the MF membrane has a contact angle against a droplet of distilled water at 20 degrees C. of at most 40 degrees, more preferably at most 30 degrees, even more preferably at most 20 degrees, and most preferably at most 15 degrees.
Numbered embodiment 24. The method according to any of the preceding numbered embodiments wherein the temperature of the mfl and MF retentate(s) derived from the mfl during the step 2) is in the range of 40-65 degrees C.; more preferably 45-65 degrees C., even more preferably 50-65 degrees C., and most preferably 50-60 degrees C.
Numbered embodiment 25. The method according to any of the preceding numbered embodiments wherein the microfiltration involves a transmembrane pressure in the range of 0.1-10 bar, more preferably 0.1-5 bar, more preferably 0.2-3 bar, even more preferably 0.3-1.0 bar, and most preferably 0.4-0.6 bar.
Numbered embodiment 26. The method according to any of the preceding numbered embodiments wherein the microfiltration involves a transmembrane pressure of at most 10 bar, more preferably at most 5 bar, more preferably at most 3 bar, even more preferably at most 1 bar, and most preferably at most 0.6 bar.
Numbered embodiment 27. The method according to any of the preceding numbered embodiments wherein the microfiltration involves a transmembrane pressure of at most 0.4 bar, more preferably at most 0.3 bar, even more preferably at most 0.2 bar, and most preferably at most 0.1 bar.
Numbered embodiment 28. The method according to any of the preceding numbered embodiments wherein the microfiltration of step 2) is arranged and operated to lose at most 2% w/w of the total fat of the mfl to the microfiltration permeate, more preferably at most 1.5% w/w, even more preferably at most 1.0% w/w, and most preferably at most 0.8% w/w.
Numbered embodiment 29. The method according to any of the preceding numbered embodiments wherein the microfiltration of step 2) is arranged and operated to lose at most 0.5% w/w of the total fat of the mfl to the microfiltration permeate, more preferably at most 0.3% w/w, even more preferably at most 0.1% w/w, and most preferably at most 0.05% w/w.
Numbered embodiment 30. The method according to any of the preceding numbered embodiments wherein the microfiltration of step 2) is arranged and operated to lose at most 45% w/w of the total phospholipid of the mfl to the microfiltration permeate, more preferably at most 30% w/w, even more preferably at most 20% w/w, and most preferably at most 16% w/W.
Numbered embodiment 31. The method according to any of the preceding numbered embodiments wherein the microfiltration of step 2) is arranged and operated to lose at most 10% w/w of the total phospholipid of the mfl to the microfiltration permeate, more preferably at most 6% w/w, even more preferably at most 4% w/w, and most preferably at most 2% w/w.
Numbered embodiment 32. The method according to any of the preceding numbered embodiments wherein the milk fat globule concentrate is subjected to a heat-treatment.
Numbered embodiment 33. A milk fat globule concentrate, preferably obtainable by one or more of claim 1-32, and which preferably comprises:
Numbered embodiment 34. The milk fat globule concentrate according to numbered embodiment 33, comprising total fat in an amount in the range of 62-85% w/w, more preferably 65-85% w/w, more preferably 70-85% w/w, even more preferably 70-82% w/w, and most preferably 75-82% w/w.
Numbered embodiment 35. The milk fat globule concentrate according to any of the numbered embodiments 33-34, comprising total protein in an amount in the range of 0.1-5% w/w, more preferably 0.2-3% w/w, even more preferably 0.3-1.5% w/w, and most preferably 0.4-1.0% w/w.
Numbered embodiment 36. The milk fat globule concentrate according to any of the numbered embodiments 33-35, comprising protein in an amount in the range of 0.4-5% w/w, more preferably 0.5-3% w/w, even more preferably 0.6-1.5% w/w, and most preferably 0.7-1.2% w/w.
Numbered embodiment 37. The milk fat globule concentrate according to numbered embodiment 33-36, comprising protein which is not bound to fat globules in an amount in the range of 0-2% w/w, more preferably 0-1% w/w, even more preferably 0-0.5% w/w, and most preferably 0-0.3% w/W.
Numbered embodiment 38. The milk fat globule concentrate according to any of numbered embodiments 33-37, having a weight ratio between casein and whey protein of 70:30-99:1, more preferably 80:20-98:2, even more preferably 85:15-98:2, and most preferably 90:10-98:2.
Numbered embodiment 39. The milk fat globule concentrate according to any of numbered embodiments 33-38, comprising carbohydrate in an amount in the range of 0-4% w/w, more preferably 0-2% w/w, even more preferably 0-1% w/w, and most preferably 0-0.5% w/w.
Numbered embodiment 40. The milk fat globule concentrate according to any of numbered embodiments 33-39, comprising lactose in an amount in the range of 0-4% w/w, more preferably 0-2% w/w, even more preferably 0-1% w/w, and most preferably 0-0.5% w/w.
Numbered embodiment 41. The milk fat globule concentrate according to any of numbered embodiments 33-40, having an ash content in the range of 0-4% w/w, more preferably 0.05-2% w/w, even more preferably 0.1-1.0% w/w, and most preferably in the range of 0.2-0.4%.
Numbered embodiment 42. The milk fat globule concentrate according to any of the numbered embodiments 33-41, having a pH in the range of 5-8, more preferably 5.5-8.0, even more preferably 6.0-7.5, and most preferably 6.4-7.0.
Numbered embodiment 43 The milk fat globule concentrate according to any of the numbered embodiments 33-42, having a pH in the range of 6.0-7.5, more preferably 6.0-7.0, even more preferably 6.4-7.0% w/w, and most preferably in the range of 6.4-6.8.
Numbered embodiment 44. The milk fat globule concentrate according to any of the numbered embodiments 33-43, having a weight ratio between total phospholipid and total fat of at least 0.0022, more preferably at least 0.0024, even more preferably at least 0.0028, and most preferably at least 0.0030.
Numbered embodiment 45. The milk fat globule concentrate according to any of the numbered embodiments 33-44, having a weight ratio between total phospholipid and total fat in the range of 0.0022-0.02, more preferably 0.0024-0.01, even more preferably 0.0028-0.007, and most preferably 0.0030-0.005.
Numbered embodiment 46. The milk fat globule concentrate according to any of the numbered embodiments 33-45, having a weight ratio between total phospholipid and total fat of at least 0.0033, more preferably at least 0.0035, even more preferably at least 0.0037, and most preferably at least 0.0038.
Numbered embodiment 47. The milk fat globule concentrate according to any of the numbered embodiments 33-46, having a weight ratio between total phospholipid and total fat of 0.0033-0.02, more preferably 0.0035-0.01, even more preferably 0.0037-0.007, and most preferably 0.0038-0.005.
Numbered embodiment 48. The milk fat globule concentrate according to any of the numbered embodiments 33-47 comprising at least 55% w/w of the total phospholipid of the mfl, more preferably at least 70% w/w, even more preferably at least 80% w/w, and most preferably at least 84% w/w.
Numbered embodiment 49. The milk fat globule concentrate according to any of the numbered embodiments 33-48 comprising at least 90% w/w of the total phospholipid of the mfl, more preferably at least 94% w/w, even more preferably at least 96% w/w, and most preferably at least 98% w/W.
Numbered embodiment 50. The milk fat globule concentrate according to any of the numbered embodiments 33-49 containing at most 10000 colony forming units per g, more preferably at most 2000 colony forming units per g, even more preferably at most 1000 colony forming units per g, and most preferably at most 500 colony forming units per g.
Numbered embodiment 51. The milk fat globule concentrate according to any of the numbered embodiments 27-39, which is obtainable by a method according to one or more of numbered embodiments 1-26.
Numbered embodiment 52. A process of preparing a butter-like milk fat-containing product (bmp), the process comprising the steps of:
Numbered embodiment 53. The process according to numbered embodiment 52, wherein step ii-a) furthermore involves blending the added ingredients with the milk fat globule concentrate and/or a subsequent product stream comprising the milk fat globule concentrate, preferably without provoking phase inversion.
Numbered embodiment 54. The process according to numbered embodiment 52 or 53, wherein step ii-b) involves holding at a temperature of at most 18 degrees C., more preferably at most 17 degrees C., and most preferably at most 15 degrees C.
Numbered embodiment 55. The process according to any of the numbered embodiments 52-54, wherein step ii-b) involves holding at a temperature of 5-20 degrees C., more preferably 10-17 degrees C., and most preferably 12-15 degrees C.
Numbered embodiment 56. The process according to any of the numbered embodiments 52-55 wherein step ii) involves:
Numbered embodiment 57. The process according to any of the numbered embodiments 52-56 wherein step ii) involves:
Numbered embodiment 58. The process according to any of the numbered embodiments 52-57 wherein step ii-d) is performed after step ii-b) and preferably prior, during and/or after step ii-c).
Numbered embodiment 59. The process according to any of the numbered embodiments 52-58, wherein the milk fat globule concentrate is used in an amount sufficient to provide at least 20% w/w of the total fat of the bmp, more preferably at least 25% w/w, even more preferably at least 30% w/w, and most preferably at least 40% w/w of the total fat of the bmp.
Numbered embodiment 60. The process according to any of the numbered embodiments 52-59, wherein the milk fat globule concentrate is used in an amount sufficient to provide at 20-60% w/w of the total fat of the bmp, more preferably at least 21-50% w/w, even more preferably 22-45% w/w, and most preferably at least 23-40% w/w of the total fat of the bmp.
Numbered embodiment 61. The process according to any of the numbered embodiments 52-60, wherein the milk fat globule concentrate is used in an amount sufficient to provide at least 50% w/w of the total fat of the bmp, more preferably at least 60% w/w, even more preferably at least 80% w/w, and most preferably at least 90% w/w of the total fat of the bmp.
Numbered embodiment 62. The process according to any of the numbered embodiments 52-61, wherein the milk fat globule concentrate is used in an amount sufficient to provide at least 95% w/w of the total fat of the bmp, more preferably at least 97% w/w, even more preferably at least 99% w/w, and most preferably approx. 100% w/w of the total fat of the bmp.
Numbered embodiment 63. The process according to any of the numbered embodiments 52-62, wherein the milk fat globule concentrate is used in an amount sufficient to provide at 50-95% w/w of the total fat of the bmp, more preferably 55-90% w/w, even more preferably 55-85% w/w, and most preferably 60-80% w/w of the total fat of the bmp.
Numbered embodiment 64. The process according to any of the numbered embodiments 52-63, wherein the bmp comprises total protein in an amount in the range of 0.1-5% w/w, more preferably 0.2-4% w/w, even more preferably 0.4-2% w/w, and most preferably 0.5-1.0% w/w.
Numbered embodiment 65. The process according to any of the numbered embodiments 52-64, wherein the bmp has a weight ratio between casein and whey protein of 70:30-99:1, more preferably 80:20-98:2, even more preferably 85:15-98:2, and most preferably 90:10-98:2.
Numbered embodiment 66. The process according to any of the numbered embodiments 52-65, wherein the bmp comprises total fat in an amount in the range of 50-90% w/w, more preferably 55-85% w/w, even more preferably 60-84% w/w, and most preferably 80-84% w/w.
Numbered embodiment 67. The process according to any of the numbered embodiments 52-66, wherein the bmp comprises total fat in an amount in the range of 35-60% w/w, more preferably 35-50% w/w, even more preferably 36-45% w/w, and most preferably 38-42% w/w.
Numbered embodiment 68. The process according to any of the numbered embodiments 52-67, wherein the bmp comprises total fat in an amount in the range of 40-80% w/w, more preferably 45-75% w/w, even more preferably 50-70% w/w, and most preferably 55-65% w/w.
Numbered embodiment 69. The process according to any of the numbered embodiments 52-68, wherein the bmp comprises carbohydrate in an amount in the range of 0-10% w/w, more preferably 0-8% w/w, even more preferably 0-6% w/w, and most preferably 0-5% w/w.
Numbered embodiment 70. The process according to any of the numbered embodiments 52-69, wherein the bmp comprises carbohydrate in an amount in the range of 0.1-10% w/w, more preferably 0.2-8% w/w, even more preferably 0.3-6% w/w, and most preferably 0.4-5% w/w.
Numbered embodiment 71. The process according to any of the numbered embodiments 52-70, wherein the bmp is a water-in-oil emulsion.
Numbered embodiment 72. The process according to any of the numbered embodiments 52-71, wherein the bmp is an oil-in-water emulsion.
Numbered embodiment 73. The process according to any of the numbered embodiments 52-72, wherein the bmp comprises both segments of oil-in-water emulsion and segments of water-in-oil emulsion.
Numbered embodiment 74. A bmp, preferably obtainable by a process according to one or more of numbered embodiments 52-73, the product comprising:
The present invention has been described above with reference to specific embodiments and aspects. However, other embodiments than the above described are equally possible within the scope of the invention. The different features and steps of various embodiments and aspects of the invention may be combined in other ways than those described herein unless it is stated otherwise.
Methods of Analysis
Analysis A: Total Protein
The concentration of protein of a composition was determined by Kjeldahl method (ISO 8968-1:2014/IDF 20) with a conversion factor of 6.25.
Analysis B: Total Fat and Dry Matter
The total fat and dry matter contents of a composition was evaluated using MilkoScan™ FT1 (Foss Electric, Hillerød, Denmark) and FoodScan™ Dairy Analyser (Foss Electric, Hillerød, Denmark).
Analysis C: Particle Size Distribution
The particle size distribution of a composition was determined using a Malvern Mastersizer 2000 (Malvern Instruments Ltd., Malvern, UK). The sample was added until an obscuration rate of 10-20% and the refractive indices for milk fat and water were 1.458 and 1.330, respectively. The D[4,3], Dv10, Dv50, and Dv90 values were calculated by the Malvern software and used to interpret the droplet size distribution.
Analysis D: Total Phospholipids
The concentration of phospholipids in the skim phase from centrifugal separation and the permeate from the membrane filtration were determined by Spectral Service AG (Köln, Germany). The samples were analysed with quantitative 31P-NMR spectroscopy using a Bruker Avance III 600 MHz instrument with automated sample changer and BBO cryoprobe. Triphenyl phosphate were used as internal standard.
Analysis E: Microstructure
The microstructure of the cream and concentrated creams was analysed using a Nikon C2 Confocal Laser Scanning Microscope (Nikon Instrument Inc, Tokyo, Japan) with a 60× objective lens. Nile red, Fluorescein isothiocyanate (FITC), and Rhodamine were used as the fluorescence stain agents for fats, proteins, and milk fat globule membrane, respectively. The fresh creams were stained with Rhodamine dissolved in acetone to a final concentration of 0.01%. Between 5 and 10 pictures were obtained for each sample to get a representative result. The creams after storage at 5° C. were labelled with Nile Red and FITC both dissolved in acetone to a final concentration of 0.001%.
Analysis F: Proteins not Bound to Fat Globules
The concentrated cream are washed by using Milli-Q water or phosphate buffer saline or simulated milk ultrafiltrate solutions at 38° C. The cream (fat phase) and aqueous solution containing protein are separated by centrifugation (Ye et al. 2002; Fong et al. 2007). The aqueous solution after washing the cream are analysed by Kjeldahl method (ISO 8968-1:2014/IDF 20) with a conversion factor of 6.25 for total protein. Furthermore, the aqueous solution containing proteins are further treated by urea, Na-citrate and DTE buffer and individual milk proteins are analysed by LC-MS.
In the experiment, the inventors prepared two samples of concentrated cream; one prepared according to the invention by microfiltration and one prepared by centrifugation.
Materials and Methods:
Materials:
Raw milk was heated to 50 degrees C. and separated into cream and skim milk fractions by centrifugation. The cream containing 38-42% fat was pasteurized (72 degrees C. for 15 seconds) and cooled down to 10 degrees C. for storage for microfiltration and centrifugal separation experiments.
Process:
The pasteurized cream was microfiltered using a ceramic membrane with nominal pore size of 0.3 micron and having a contact angle against a droplet of distilled water at 20 degrees C. of approx. 15 degrees. Prior to the filtration experiment, the cream was heated to approximately 55 degrees C. and the filtration was carried out in a feed and bleed mode (2 L of feed added when 2 L of permeate was recovered) at a constant transmembrane pressure of at approximately 50 degrees C. until the volumetric concentration factor of 2 to 2.5. The permeate flux was controlled by applying a back-pressure using a needle valve in the permeate side of the membrane.
For comparison the pasteurized cream was also concentrated using centrifugal separator (Tetra Pak, Denmark). The cream was heated at 75 degrees C. and fed to the separator at the flow rate of 750 L/h. The cream was concentrated at the speed of 6185 rpm. The out let temperature was 72-74 degrees C.
Characterisation:
The cream (raw material), the concentrated cream prepared by microfiltration, the concentrated cream prepared by centrifugation, the microfiltration permeate, and the skim milk obtained from centrifugation were characterised with respect to texture, chemical composition and microstructure as discussed in the previous section (Methods of Analysis).
Results:
During production of the concentrated cream, the texture was like a very viscous liquid. Most surprisingly, the texture and spreadability properties of the cold stored cream from microfiltration were found to be surprisingly similar to that of butter. This is demonstrated in
The fat and protein contents of the concentrated cream from microfiltration (in Table 1) were found to be 78.16 and 3.21%, respectively. The fat concentration of the concentrated cream was similar to that of microfiltration but the protein concentration was three times lower. Similarly, the fat content in the permeate side was found to be very low in the microfiltration permeate and the skim phase from centrifugation. However, the microfiltration process retained more proteins in the concentrated cream leaving relatively lower amount of proteins in the permeate compared to that of skim phase from centrifugation. The concentration of protein in the concentrated cream using microfiltration could easily be lowered using a higher pore size membrane.
The particle size distribution of the feed and concentrated cream are shown in
The images from confocal microscopy showed a considerable differences in the microstructures between the samples from microfiltration and centrifugation (
Mechanical stress applied to milk and cream leads to the shear damage to the milk fat globule membrane. Subsequently, the phospholipids are released from the damaged fat globule membranes. To estimate the potential damage of the milk fat globules due to processing of the cream, the phospholipid content in the microfiltration permeate and the skim phase of the centrifugation were analysed (Table 2). If the fat globules are damaged, phospholipids could be liberated into the serum phase and hence be removed along with the skim phase during centrifugal separation or permeate during filtration. The results showed that the skim phase had 0.05% (w/w) of phospholipids which is at least 15 times higher than in the permeate of the microfiltration. This suggests that the concentrated cream from microfiltration contains a higher amount of phospholipids compared to centrifugal separation.
In the conventional butter making process, buttermilk is produced as a side stream which has a high concentration of phospholipids due to churning. According to Britten et al. (International Journal of Food Science and Technology 2008, 43, 651-657) the phospholipids concentration in buttermilk is about 0.134% and only 54% of the phospholipids present in the cream are recovered in the final product. The concentration of phospholipids in the concentrated cream as described in the present example where buttermilk is replaced by either skim phase by centrifugation or permeate by microfiltration had surprisingly less amount of phospholipid loss. The final phospholipids in the butter using the conventional process was 0.165% with phospholipids to fat ratio of 0.00206 (table 3). The phospholipid content could be increased by 53% (0.253% and phospholipid to fat ratio of 0.00316) using centrifugation. This could even be further increased by 83% (0.302% and phospholipid to fat ratio of 0.00377). It seems that more than 98% of phospholipids present in the cream could be recovered in the final product using microfiltration compared to 83% from the centrifugation.
Conclusion:
The inventors have found that microfiltration can be used to concentrate cream to reach to final fat content of more than 60%. Microfiltration can be operated as a gentle process to cause minimum damage to milk fat globules of the concentrated cream. In addition, the obtained concentrated cream has unique properties in terms of milk fat globule structure, composition especially in terms of phospholipids and texture which is applicable as a raw material for e.g. butter and milk fat containing blends. Interestingly the concentrated cream can be used as a high quality butter spread without any further processing and has sensory properties that are surprisingly similar to quality butter.
This experiment describes how to use the concentrated cream obtained from Example 1 for preparing a high quality lactic salted butter product.
Materials and Methods:
Materials:
Process:
Concentrated cream is obtained by the process described in Example 1 at a temperature of about 50 degrees C. The concentrated cream is cooled to 15 degrees C. and kept at that temperature for 120 minutes in order for sufficient fat crystal formation to take place. After this crystallization step, a mixture of dry micro-salt and fermented milk is added in-line during mixing with a SPX DAR mixer. The purpose of this mixing is a partial phase inversion from an oil-in-water type emulsion to a water-in-oil type emulsion.
After the phase inversion, the product is cooled to 12 degrees C. by means of a Scraped Surface Heat Exchanger (SSHE) and subsequently filled in retail packages. The final product is cooled to 5 degrees C. in a cold storage warehouse.
Characterisation:
The resulting butter is analysed using physical and sensory analyses in order to confirm the presence of the desired water-in-oil emulsion and desired physical and sensory properties.
Conclusion:
The resulting butter is a lactic, salted butter (predominately in the form of a water-in-oil emulsion) with good sensory properties due to the gentle treatment (and optimal composition) of the concentrated cream. An additional major advantage of this process is the fact, that side streams (i.e. buttermilk) is avoided.
This experiment describes how to use the concentrated cream obtained from Example 1 for preparing a high quality butter fat spread with a total fat content of 72% of which 26% is vegetable fat (relative to total fat) and 74% is milk fat (relative to total fat).
Materials and Methods:
Materials:
Process:
Concentrated cream with a fat content of approximately 75% is obtained by the process described in Example 1 at a temperature of about 50 degrees C. The cream is cooled to 15 degrees C. and kept at that temperature for 120 minutes in order for sufficient fat crystal formation to take place. After this crystallization step, a mixture of dry micro-salt and fermented milk as well as 50% of the total amount of rapeseed oil is added in-line during mixing with a SPX DAR mixer. The purpose of this mixing is to obtain partial phase inversion from an oil-in-water type emulsion to a water-in-oil type emulsion. After the phase inversion, the remaining 50% of rapeseed oil is added during mixing with the SPX DAR mixer.
The product is cooled to 12 degrees C. by means of a Scraped Surface Heat Exchanger (SSHE) and subsequently filled in retail packages. The final product is cooled to 5 degrees C. in a cold storage warehouse.
Characterisation:
The resulting butter fat spread is analysed using physical and sensory analyses in order to confirm the presence of the desired water-in-oil emulsion, and desired physical and sensory properties.
Conclusion:
The resulting butter fat spread is a lactic, salted butter fat spread (predominantly in the form of a water-in-oil emulsion) with good sensory properties due to the gentle treatment (and optimal composition) of the concentrated cream.
A major advantage of this process is the fact, that side streams (i.e. buttermilk) is avoided.
| Number | Date | Country | Kind |
|---|---|---|---|
| 21165328.2 | Mar 2021 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2022/058017 | 3/25/2022 | WO |
